Literature DB >> 2861731

Selective disappearance of histamine H2-receptor activity in the human gastric cancer cell line HGT-1 after short-term or chronic treatment by histamine or its H2-antagonists.

S Emami, C Gespach, H Bodéré.   

Abstract

Homologous loss of histamine H2-receptor activity (cAMP generation) was observed after short-term (10-20 min) or chronic treatment (6 days) of cultured HGT-1 cells with histamine (desensitization) or the H2-receptor antagonist SKF 93479. This inactivation process was not observed when HGT-1 cells were exposed to the classical H2-antihistamine cimetidine. The data show: (1) that the compound SKF 93479 has a very prolonged inhibitory action on histamine receptor activity, suggesting an irreversible interaction between the antagonist and the receptor; (2) that cimetidine is a reversible H2-receptor antagonist which can be removed without changing the the efficacy and the potency of histamine on gastric cells; (3) that the H2-receptor antagonists cimetidine and SKF 93479 specifically block histamine H2-receptor activity in HGT-1 cells since cAMP generation induced by other hormones such as vasoactive intestinal peptide (VIP), glucagon or gastric inhibitory peptide (GIP) was unchanged after treatment; (4) the first evidence for time-dependent (half-life: 20 min) desensitization of gastric H2-receptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861731     DOI: 10.1007/bf01983137

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  8 in total

1.  Regulation by vasoactive intestinal peptide of cyclic AMP accumulation in gastric epithelial glands. A characteristic of human stomach.

Authors:  C Dupont; C Gespach; B Chenut; G Rosselin
Journal:  FEBS Lett       Date:  1980-04-21       Impact factor: 4.124

2.  Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide.

Authors:  D Bataille; K Tatemoto; C Gespach; H Jörnvall; G Rosselin; V Mutt
Journal:  FEBS Lett       Date:  1982-09-06       Impact factor: 4.124

3.  Gastric inhibitory peptide (GIP), pancreatic glucagon and vasoactive intestinal peptide (VIP) are cAMP-inducing hormones in the human gastric cancer cell line HGT-1. Homologous desensitization of VIP receptor activity.

Authors:  C Gespach; S Emami; G Rosselin
Journal:  Biochem Biophys Res Commun       Date:  1984-04-30       Impact factor: 3.575

4.  The interaction of glucagon, gastric inhibitory peptide and somatostatin with cyclic AMP production systems present in rat gastric glands.

Authors:  C Gespach; D Bataille; M C Dutrillaux; G Rosselin
Journal:  Biochim Biophys Acta       Date:  1982-02-10

5.  Histamine and VIP interactions with receptor-cyclic AMP systems in the human gastric cancer cell line HGT-1.

Authors:  S Emami; C Gespach; M E Forgue-Lafitte; Y Broer; G Rosselin
Journal:  Life Sci       Date:  1983-08-01       Impact factor: 5.037

6.  Comparison of antisecretory potency and duration of action of the H2-receptor antagonists AH 22216, cimetidine, ranitidine and SK & F 93479 in the dog.

Authors:  R Stables; M J Daly; J M Humphray
Journal:  Agents Actions       Date:  1983-04

7.  Regulation by vasoactive intestinal peptide, histamine, somatostatin-14 and -28 of cyclic adenosine monophosphate levels in gastric glands isolated from the guinea pig fundus or antrum.

Authors:  C Gespach; D Hui Bon Hoa; G Rosselin
Journal:  Endocrinology       Date:  1983-05       Impact factor: 4.736

8.  Characterization of a newly established human gastric cancer cell line HGT-1 bearing histamine H2-receptors.

Authors:  C L Laboisse; C Augeron; M H Couturier-Turpin; C Gespach; A M Cheret; F Potet
Journal:  Cancer Res       Date:  1982-04       Impact factor: 12.701

  8 in total
  5 in total

1.  VIP and histamine H2 receptor activity in human fetal gastric glands.

Authors:  S Emami; E Chastre; N Mulliez; M Gonzales; C Gespach
Journal:  Experientia       Date:  1986-04-15

2.  Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth.

Authors:  W J Adams; J A Lawson; D L Morris
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

3.  Blood histamine and solid malignant tumors.

Authors:  C M Moriarty; J L Stucky; K W Hamburger; K D Patil; J F Foley; R R Koefoot
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

4.  Desensitization by histamine of H2 receptor activity in HGT-1 human cancerous gastric cells.

Authors:  S Emami; C Gespach
Journal:  Agents Actions       Date:  1986-04

5.  Ranitidine and cimetidine differ in their in vitro and in vivo effects on human colonic cancer growth.

Authors:  J A Lawson; W J Adams; D L Morris
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.